Filter
469
Text search:
Delta
Featured
52
149
Language
Document type
190
95
88
23
23
19
15
6
3
2
2
2
1
Countries / Regions
53
44
31
20
12
12
10
8
8
6
6
5
5
5
4
4
4
4
4
4
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
257
17
14
11
10
9
6
1
Toolboxes
146
31
22
12
12
11
10
7
7
6
6
6
6
5
3
3
2
2
2
2
2
1
1
SARS-CoV-2 infections among children and adolescents cause less severe illness and fewer deaths compared to adults. While a less severe course of infection is a positive outcome, there are concerns that mild symptoms may have led to less testing, resulting in fewer identified cases of COVID-19 in ch
...
Les infections au SRAS-CoV-2 chez les enfants et les adolescents provoquent une maladie moins grave et moins de décès que chez les adultes. Bien qu'une évolution moins grave de l'infection soit un résultat positif, on s'inquiète du fait que des symptômes légers aient pu conduire à moins de t
...
Every country has been affected by COVID-19, with nearly a quarter
of a billion cases and almost 5 million deaths reported globally as of
end of September 2021. Despite the stunning speed with which highly
effective and safe vaccines have been developed, new waves of disease
are still pushin
...
La détection directe des protéines virales du SRAS-CoV-2 (antigènes) dans les écouvillons nasaux et autres sécrétions respiratoires à l'aide de tests immunologiques à flux latéral (également appelés tests de diagnostic rapide, TDR) offre une méthode plus rapide et moins coûteuse pour te
...
National Operationalisation Plan for the COVID-19 Vaccine : 13th edition
Dexametasona para tratamento de pacientes com COVID-19
Semana Epidemiológica 45 • 7/11 a 13/11/2021
Why bold action against inequalities is needed to en AIDS, stop COVID-19 and prepare for future pandemics
These WHO interim recommendations for use of the COVID-19 vaccine BIBP produced by Sinopharm were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
Th
...
11 august 2022, updated version
(Synthesis Report 2021) [EN] - World Analysis on World about Agriculture, Climate Change and Environment, Drought, Flood and more; published on 09 Dec 2021 by FAO
Expertise on #24 – Climate & Biodiversity - Expertise France
Overview
16 Dec 2021. This interim guidance pertains to heterologous primary and heterologous boosting schedules of Covid-19 vaccines. It focuses on heterologous schedules combining multiple vaccine platforms (e.g. a vectored vaccine followed by an mRNA vaccine).
27 September 2022
These WHO interim recommendations for use of the Novavax NVX-CoV2373 vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
Comirnaty® 10 μg und 30 μg von BioNTech / Pfizer und Spikevax® von Moderna
Stand 21. Dezember 2021
